About

Areas of specialism

Health Economics; Decision modelling; Clincal trials

My qualifications

BA (Hons), Economics
Durham University
MSc Health Economics
University of York
PhD, Health Economics
Brunel University London

Research

Research interests

Publications

Mirthe Muilwijk, Marie Loh, Samreen Siddiqui, Sara Mahmood, Saranya Palaniswamy, Khurram Shahzad, Lathika K Athauda, Ranil Jayawardena, Tayyaba Batool, Saira Burney, Matthew Glover, Vodathi Bamunuarachchi, Manju Panda, Madawa Madawanarachchi, Baldeesh Rai, Iqra Sattar, Wnurinham Silva, Swati Waghdhare, Marjo-Riitta Jarvelin, Ravindra Prasan Rannan-Eliya, Nilmini Wijemunige, Heather M Gage, Jonathan Valabhji, Gary S Frost, Rajitha Wickremasinghe, Anuradhani Kasturiratne, Khadija I Khawaja, Sajjad Ahmad, Irene Gm van Valkengoed, Prasad Katulanda, Sujeet Jha, Jaspal S Kooner, John C Chambers (2021)Effects of a lifestyle intervention programme after 1 year of follow-up among South Asians at high risk of type 2 diabetes: a cluster randomised controlled trial, In: BMJ global health6e006479 BMJ

South Asians are at high risk of type 2 diabetes (T2D). We assessed whether intensive family-based lifestyle intervention leads to significant weight loss, improved glycaemia and blood pressure in adults at elevated risk for T2D. This cluster randomised controlled trial (iHealth-T2D) was conducted at 120 locations across India, Pakistan, Sri Lanka and the UK. We included 3684 South Asian men and women, aged 40-70 years, without T2D but with raised haemoglobin A1c (HbA1c) and/or waist circumference. Participants were randomly allocated either to the family-based lifestyle intervention or control group by location clusters. Participants in the intervention received 9 visits and 13 telephone contacts by community health workers over 1-year period, and the control group received usual care. Reductions in weight (aim >7% reduction), waist circumference (aim ≥5 cm reduction), blood pressure and HbA1C at 12 months of follow-up were assessed. Our linear mixed-effects regression analysis was based on intention-to-treat principle and adjusted for age, sex and baseline values. There were 1846 participants in the control and 1838 in the intervention group. Between baseline and 12 months, mean weight of participants in the intervention group reduced by 1.8 kg compared with 0.4 kg in the control group (adjusted mean difference -1.10 kg (95% CI -1.70 to -1.06), p

Anuradhani Kasturiratne, Khadija I Khawaja, Sajjad Ahmad, Samreen Siddiqui, Khurram Shahzad, Lathika K Athauda, Ranil Jayawardena, Sara Mahmood, Mirthe Muilwijk, Tayyaba Batool, Saira Burney, Matthew Glover, Saranya Palaniswamy, Vodathi Bamunuarachchi, Manju Panda, Suren Madawanarachchi, Baldeesh Rai, Iqra Sattar, Wnurinham Silva, Swati Waghdhare, Marjo-Riitta Jarvelin, Ravindra P Rannan-Eliya, Heather M Gage, Irene G M van Valkengoed, Jonathan Valabhji, Gary S Frost, Marie Loh, Ananda R Wickremasinghe, Jaspal S Kooner, Prasad Katulanda, Sujeet Jha, John C Chambers (2021)The iHealth-T2D study, prevention of type 2 diabetes amongst South Asians with central obesity and prediabetes: study protocol for a randomised controlled trial, In: Trials22928

People from South Asia are at increased risk of type 2 diabetes (T2D). There is an urgent need to develop approaches for the prevention of T2D in South Asians that are cost-effective, generalisable and scalable across settings. Compared to usual care, the risk of T2D can be reduced amongst South Asians with central obesity or raised HbA1c, through a 12-month lifestyle modification programme delivered by community health workers. Cluster randomised clinical trial (1:1 allocation to intervention or usual care), carried out in India, Pakistan, Sri Lanka and the UK, with 30 sites per country (120 sites total). Target recruitment 3600 (30 participants per site) with annual follow-up for 3 years. South Asian, men or women, age 40-70 years with (i) central obesity (waist circumference ≥ 100 cm in India and Pakistan; ≥90 cm in Sri Lanka) and/or (ii) prediabetes (HbA1c 6.0-6.4% inclusive). known type 1 or 2 diabetes, normal or underweight (body mass index